Risedronate Reduces the Risk of First Vertebral Fracture in Osteoporotic Women View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2002-06

AUTHORS

R. P. Heaney, T. M. Zizic, I. Fogelman, W. P. Olszynski, P. Geusens, C. Kasibhatla, N. Alsayed, G. Isaia, M. W. Davie, C. H. Chesnut III

ABSTRACT

:Risedronate treatment reduces the risk of vertebral fracture in women with existing vertebral fractures, but its efficacy in prevention of the first vertebral fracture in women with osteoporosis but without vertebral fractures has not been determined. We examined the risk of first vertebral fracture in postmenopausal women who were enrolled in four placebo-controlled clinical trials of risedronate and who had low lumbar spine bone mineral density (BMD) (mean T-score =–3.3) and no vertebral fractures at baseline. Subjects received risedronate 5 mg (n= 328) or placebo (n= 312) daily for up to 3 years; all subjects were given calcium (1000 mg daily), as well as vitamin D supplementation (up to 500 IU daily) if baseline serum 25-hydroxyvitamin D levels were low. The incidence of first vertebral fracture was 9.4% in the women treated with placebo and 2.6% in those treated with risedronate 5 mg (risk reduction of 75%, 95% confidence interval 37% to 90%; P= 0.002). The number of patients who would need to be treated to prevent one new vertebral fracture is 15. When subjects were stratified by age, similar significant reductions were observed in patients with a mean age of 64 years (risk reduction of 70%, 95% CI 8% to 90%; P= 0.030) and in those with a mean age of 76 years (risk reduction of 80%, 95% CI 7% to 96%; P= 0.024). Risedronate treatment therefore significantly reduces the risk of first vertebral fracture in postmenopausal women with osteoporosis, with a similar magnitude of effect early and late after the menopause. More... »

PAGES

501-505

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s001980200061

DOI

http://dx.doi.org/10.1007/s001980200061

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1037244334

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/12107665


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Calcium", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Calcium Channel Blockers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Etidronic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fractures, Bone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoporosis, Postmenopausal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risedronic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vitamin D", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Creighton University, Omaha, Nebraska, USA, USA", 
          "id": "http://www.grid.ac/institutes/grid.254748.8", 
          "name": [
            "Creighton University, Omaha, Nebraska, USA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heaney", 
        "givenName": "R. P.", 
        "id": "sg:person.0645437522.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645437522.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chesapeake Medical Research, Baltimore, Maryland, USA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Chesapeake Medical Research, Baltimore, Maryland, USA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zizic", 
        "givenName": "T. M.", 
        "id": "sg:person.01056550173.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056550173.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Guy\u2019s Hospital, London, UK, UK", 
          "id": "http://www.grid.ac/institutes/grid.239826.4", 
          "name": [
            "Guy\u2019s Hospital, London, UK, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fogelman", 
        "givenName": "I.", 
        "id": "sg:person.0655217537.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655217537.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Midtown Medical Center, Saskatoon, Saskatchewan, Canada, Canada", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Midtown Medical Center, Saskatoon, Saskatchewan, Canada, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Olszynski", 
        "givenName": "W. P.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Limburg University Center, Diepenbeek, Belgium, and University Hospital, Maastricht, The Netherlands, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.412966.e", 
          "name": [
            "Limburg University Center, Diepenbeek, Belgium, and University Hospital, Maastricht, The Netherlands, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Geusens", 
        "givenName": "P.", 
        "id": "sg:person.016652646157.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016652646157.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, USA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418758.7", 
          "name": [
            "Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, USA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kasibhatla", 
        "givenName": "C.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, USA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418758.7", 
          "name": [
            "Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, USA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Alsayed", 
        "givenName": "N.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Turin, Turin, Italy, Italy", 
          "id": "http://www.grid.ac/institutes/grid.7605.4", 
          "name": [
            "University of Turin, Turin, Italy, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Isaia", 
        "givenName": "G.", 
        "id": "sg:person.010057222557.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010057222557.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Charles Salt Centre, Oswestry, Shropshire, UK;, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Charles Salt Centre, Oswestry, Shropshire, UK;, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Davie", 
        "givenName": "M. W.", 
        "id": "sg:person.015456062106.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015456062106.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Washington, Seattle, Washington, USA, USA", 
          "id": "http://www.grid.ac/institutes/grid.34477.33", 
          "name": [
            "University of Washington, Seattle, Washington, USA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chesnut III", 
        "givenName": "C. H.", 
        "id": "sg:person.012100475647.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012100475647.55"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s001980050218", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027968412", 
          "https://doi.org/10.1007/s001980050218"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s001980050067", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025436726", 
          "https://doi.org/10.1007/s001980050067"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2002-06", 
    "datePublishedReg": "2002-06-01", 
    "description": "Abstract:Risedronate treatment reduces the risk of vertebral fracture in women with existing vertebral fractures, but its efficacy in prevention of the first vertebral fracture in women with osteoporosis but without vertebral fractures has not been determined. We examined the risk of first vertebral fracture in postmenopausal women who were enrolled in four placebo-controlled clinical trials of risedronate and who had low lumbar spine bone mineral density (BMD) (mean T-score =\u20133.3) and no vertebral fractures at baseline. Subjects received risedronate 5 mg (n= 328) or placebo (n= 312) daily for up to 3 years; all subjects were given calcium (1000 mg daily), as well as vitamin D supplementation (up to 500 IU daily) if baseline serum 25-hydroxyvitamin D levels were low. The incidence of first vertebral fracture was 9.4% in the women treated with placebo and 2.6% in those treated with risedronate 5 mg (risk reduction of 75%, 95% confidence interval 37% to 90%; P= 0.002). The number of patients who would need to be treated to prevent one new vertebral fracture is 15. When subjects were stratified by age, similar significant reductions were observed in patients with a mean age of 64 years (risk reduction of 70%, 95% CI 8% to 90%; P= 0.030) and in those with a mean age of 76 years (risk reduction of 80%, 95% CI 7% to 96%; P= 0.024). Risedronate treatment therefore significantly reduces the risk of first vertebral fracture in postmenopausal women with osteoporosis, with a similar magnitude of effect early and late after the menopause.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s001980200061", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100834", 
        "issn": [
          "0937-941X", 
          "1433-2965"
        ], 
        "name": "Osteoporosis International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "first vertebral fracture", 
      "vertebral fractures", 
      "bone mineral density", 
      "risedronate treatment", 
      "postmenopausal women", 
      "mean age", 
      "low lumbar spine bone mineral density", 
      "lumbar spine bone mineral density", 
      "placebo-controlled clinical trial", 
      "spine bone mineral density", 
      "new vertebral fractures", 
      "vitamin D supplementation", 
      "number of patients", 
      "similar significant reductions", 
      "D supplementation", 
      "baseline serum", 
      "osteoporotic women", 
      "D levels", 
      "clinical trials", 
      "mineral density", 
      "risedronate", 
      "women", 
      "placebo", 
      "patients", 
      "osteoporosis", 
      "significant reduction", 
      "risk", 
      "age", 
      "fractures", 
      "subjects", 
      "treatment", 
      "years", 
      "menopause", 
      "similar magnitude", 
      "incidence", 
      "trials", 
      "baseline", 
      "supplementation", 
      "serum", 
      "prevention", 
      "efficacy", 
      "calcium", 
      "levels", 
      "reduction", 
      "effect", 
      "number", 
      "magnitude", 
      "density"
    ], 
    "name": "Risedronate Reduces the Risk of First Vertebral Fracture in Osteoporotic Women", 
    "pagination": "501-505", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1037244334"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s001980200061"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "12107665"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s001980200061", 
      "https://app.dimensions.ai/details/publication/pub.1037244334"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_360.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s001980200061"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s001980200061'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s001980200061'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s001980200061'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s001980200061'


 

This table displays all metadata directly associated to this object as RDF triples.

255 TRIPLES      21 PREDICATES      90 URIs      80 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s001980200061 schema:about N014730226dae4d7788f1bb76e14cef2b
2 N2b01797ed72a4f188d14103e09ef773b
3 N3d00541069724cf8b3571b71fbc723a6
4 N49711dcd6f404086ad35f681ef327c61
5 N548d65584963495f933d2f270173573a
6 N5d8e6c12ba4545c59bbf016a77d92c0d
7 N72e725259aca4d44be52fecfba789f09
8 N7e791d825fcb495aa59c3b72d45f2809
9 N92d960d4ef044219b0624f10a4e5863c
10 Nc06ca5c729b04de1bcd98c6881512598
11 Nc0efa63b7d264bde865680956a46b97b
12 Ncbf9c94bba9a47f196ddaabb947e7027
13 Nd7083bddaa6a4236ae82303bf11dc604
14 Ne57285305ffc4050adbb03c4afb56e42
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author N45e431ef2f1345d58f4e78938e1abca6
18 schema:citation sg:pub.10.1007/s001980050067
19 sg:pub.10.1007/s001980050218
20 schema:datePublished 2002-06
21 schema:datePublishedReg 2002-06-01
22 schema:description Abstract:Risedronate treatment reduces the risk of vertebral fracture in women with existing vertebral fractures, but its efficacy in prevention of the first vertebral fracture in women with osteoporosis but without vertebral fractures has not been determined. We examined the risk of first vertebral fracture in postmenopausal women who were enrolled in four placebo-controlled clinical trials of risedronate and who had low lumbar spine bone mineral density (BMD) (mean T-score =–3.3) and no vertebral fractures at baseline. Subjects received risedronate 5 mg (n= 328) or placebo (n= 312) daily for up to 3 years; all subjects were given calcium (1000 mg daily), as well as vitamin D supplementation (up to 500 IU daily) if baseline serum 25-hydroxyvitamin D levels were low. The incidence of first vertebral fracture was 9.4% in the women treated with placebo and 2.6% in those treated with risedronate 5 mg (risk reduction of 75%, 95% confidence interval 37% to 90%; P= 0.002). The number of patients who would need to be treated to prevent one new vertebral fracture is 15. When subjects were stratified by age, similar significant reductions were observed in patients with a mean age of 64 years (risk reduction of 70%, 95% CI 8% to 90%; P= 0.030) and in those with a mean age of 76 years (risk reduction of 80%, 95% CI 7% to 96%; P= 0.024). Risedronate treatment therefore significantly reduces the risk of first vertebral fracture in postmenopausal women with osteoporosis, with a similar magnitude of effect early and late after the menopause.
23 schema:genre article
24 schema:isAccessibleForFree false
25 schema:isPartOf Nd09b04b55bff4705a9f550b0f0a15d77
26 Nef8d039141a6444785ae3ccea6678de5
27 sg:journal.1100834
28 schema:keywords D levels
29 D supplementation
30 age
31 baseline
32 baseline serum
33 bone mineral density
34 calcium
35 clinical trials
36 density
37 effect
38 efficacy
39 first vertebral fracture
40 fractures
41 incidence
42 levels
43 low lumbar spine bone mineral density
44 lumbar spine bone mineral density
45 magnitude
46 mean age
47 menopause
48 mineral density
49 new vertebral fractures
50 number
51 number of patients
52 osteoporosis
53 osteoporotic women
54 patients
55 placebo
56 placebo-controlled clinical trial
57 postmenopausal women
58 prevention
59 reduction
60 risedronate
61 risedronate treatment
62 risk
63 serum
64 significant reduction
65 similar magnitude
66 similar significant reductions
67 spine bone mineral density
68 subjects
69 supplementation
70 treatment
71 trials
72 vertebral fractures
73 vitamin D supplementation
74 women
75 years
76 schema:name Risedronate Reduces the Risk of First Vertebral Fracture in Osteoporotic Women
77 schema:pagination 501-505
78 schema:productId N078f8b6324f3413cac6071876cfaadb7
79 N316ec7365fb142e19134c7c766d9b12c
80 N3e57c55ccadc45f2bf7120ff75b8b7b8
81 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037244334
82 https://doi.org/10.1007/s001980200061
83 schema:sdDatePublished 2022-08-04T16:55
84 schema:sdLicense https://scigraph.springernature.com/explorer/license/
85 schema:sdPublisher N5b4b360842074c6f9140e9eb8cb156cf
86 schema:url https://doi.org/10.1007/s001980200061
87 sgo:license sg:explorer/license/
88 sgo:sdDataset articles
89 rdf:type schema:ScholarlyArticle
90 N014730226dae4d7788f1bb76e14cef2b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Calcium
92 rdf:type schema:DefinedTerm
93 N0402eee07d184a7f8602efa8f41f0887 schema:affiliation grid-institutes:None
94 schema:familyName Olszynski
95 schema:givenName W. P.
96 rdf:type schema:Person
97 N078f8b6324f3413cac6071876cfaadb7 schema:name pubmed_id
98 schema:value 12107665
99 rdf:type schema:PropertyValue
100 N2b01797ed72a4f188d14103e09ef773b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Aged
102 rdf:type schema:DefinedTerm
103 N316ec7365fb142e19134c7c766d9b12c schema:name dimensions_id
104 schema:value pub.1037244334
105 rdf:type schema:PropertyValue
106 N3d00541069724cf8b3571b71fbc723a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Risk
108 rdf:type schema:DefinedTerm
109 N3e57c55ccadc45f2bf7120ff75b8b7b8 schema:name doi
110 schema:value 10.1007/s001980200061
111 rdf:type schema:PropertyValue
112 N3e7cf07176314e79815d4ccff0eac28c rdf:first sg:person.015456062106.13
113 rdf:rest Nfa31ffe8ea9a4d2aa2f5b67d5ccc6953
114 N440c8a740f5c45c3908730d692ab20cb rdf:first sg:person.01056550173.58
115 rdf:rest N90e9761cbd894ce2a4f5a4af853e3947
116 N45e431ef2f1345d58f4e78938e1abca6 rdf:first sg:person.0645437522.96
117 rdf:rest N440c8a740f5c45c3908730d692ab20cb
118 N4670738541b04cebb0fb54ba739ce5b0 rdf:first sg:person.016652646157.48
119 rdf:rest N67c784cc19184ff9ae140701fb254af0
120 N49711dcd6f404086ad35f681ef327c61 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Middle Aged
122 rdf:type schema:DefinedTerm
123 N4ffb870aad3548f19f660b5f019eb8b0 rdf:first sg:person.010057222557.25
124 rdf:rest N3e7cf07176314e79815d4ccff0eac28c
125 N548d65584963495f933d2f270173573a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Etidronic Acid
127 rdf:type schema:DefinedTerm
128 N5b4b360842074c6f9140e9eb8cb156cf schema:name Springer Nature - SN SciGraph project
129 rdf:type schema:Organization
130 N5d8e6c12ba4545c59bbf016a77d92c0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Risedronic Acid
132 rdf:type schema:DefinedTerm
133 N67c784cc19184ff9ae140701fb254af0 rdf:first Ne15e57c5678d446fa8d52e6e916ab6a4
134 rdf:rest N74b70ef84bac490385342fedfc60d509
135 N72e725259aca4d44be52fecfba789f09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Calcium Channel Blockers
137 rdf:type schema:DefinedTerm
138 N74b70ef84bac490385342fedfc60d509 rdf:first Nc6146c4bd2f84ec2b92eb9c76c38b8e4
139 rdf:rest N4ffb870aad3548f19f660b5f019eb8b0
140 N7e791d825fcb495aa59c3b72d45f2809 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Fractures, Bone
142 rdf:type schema:DefinedTerm
143 N7ea8bbdc17d64029a8a8f07d87a2a6f9 rdf:first N0402eee07d184a7f8602efa8f41f0887
144 rdf:rest N4670738541b04cebb0fb54ba739ce5b0
145 N90e9761cbd894ce2a4f5a4af853e3947 rdf:first sg:person.0655217537.21
146 rdf:rest N7ea8bbdc17d64029a8a8f07d87a2a6f9
147 N92d960d4ef044219b0624f10a4e5863c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Osteoporosis, Postmenopausal
149 rdf:type schema:DefinedTerm
150 Nc06ca5c729b04de1bcd98c6881512598 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Female
152 rdf:type schema:DefinedTerm
153 Nc0efa63b7d264bde865680956a46b97b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Vitamin D
155 rdf:type schema:DefinedTerm
156 Nc6146c4bd2f84ec2b92eb9c76c38b8e4 schema:affiliation grid-institutes:grid.418758.7
157 schema:familyName Alsayed
158 schema:givenName N.
159 rdf:type schema:Person
160 Ncbf9c94bba9a47f196ddaabb947e7027 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Humans
162 rdf:type schema:DefinedTerm
163 Nd09b04b55bff4705a9f550b0f0a15d77 schema:issueNumber 6
164 rdf:type schema:PublicationIssue
165 Nd7083bddaa6a4236ae82303bf11dc604 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Time Factors
167 rdf:type schema:DefinedTerm
168 Ne15e57c5678d446fa8d52e6e916ab6a4 schema:affiliation grid-institutes:grid.418758.7
169 schema:familyName Kasibhatla
170 schema:givenName C.
171 rdf:type schema:Person
172 Ne57285305ffc4050adbb03c4afb56e42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Bone Density
174 rdf:type schema:DefinedTerm
175 Nef8d039141a6444785ae3ccea6678de5 schema:volumeNumber 13
176 rdf:type schema:PublicationVolume
177 Nfa31ffe8ea9a4d2aa2f5b67d5ccc6953 rdf:first sg:person.012100475647.55
178 rdf:rest rdf:nil
179 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
180 schema:name Medical and Health Sciences
181 rdf:type schema:DefinedTerm
182 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
183 schema:name Clinical Sciences
184 rdf:type schema:DefinedTerm
185 sg:journal.1100834 schema:issn 0937-941X
186 1433-2965
187 schema:name Osteoporosis International
188 schema:publisher Springer Nature
189 rdf:type schema:Periodical
190 sg:person.010057222557.25 schema:affiliation grid-institutes:grid.7605.4
191 schema:familyName Isaia
192 schema:givenName G.
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010057222557.25
194 rdf:type schema:Person
195 sg:person.01056550173.58 schema:affiliation grid-institutes:None
196 schema:familyName Zizic
197 schema:givenName T. M.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056550173.58
199 rdf:type schema:Person
200 sg:person.012100475647.55 schema:affiliation grid-institutes:grid.34477.33
201 schema:familyName Chesnut III
202 schema:givenName C. H.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012100475647.55
204 rdf:type schema:Person
205 sg:person.015456062106.13 schema:affiliation grid-institutes:None
206 schema:familyName Davie
207 schema:givenName M. W.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015456062106.13
209 rdf:type schema:Person
210 sg:person.016652646157.48 schema:affiliation grid-institutes:grid.412966.e
211 schema:familyName Geusens
212 schema:givenName P.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016652646157.48
214 rdf:type schema:Person
215 sg:person.0645437522.96 schema:affiliation grid-institutes:grid.254748.8
216 schema:familyName Heaney
217 schema:givenName R. P.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645437522.96
219 rdf:type schema:Person
220 sg:person.0655217537.21 schema:affiliation grid-institutes:grid.239826.4
221 schema:familyName Fogelman
222 schema:givenName I.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655217537.21
224 rdf:type schema:Person
225 sg:pub.10.1007/s001980050067 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025436726
226 https://doi.org/10.1007/s001980050067
227 rdf:type schema:CreativeWork
228 sg:pub.10.1007/s001980050218 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027968412
229 https://doi.org/10.1007/s001980050218
230 rdf:type schema:CreativeWork
231 grid-institutes:None schema:alternateName Charles Salt Centre, Oswestry, Shropshire, UK;, UK
232 Chesapeake Medical Research, Baltimore, Maryland, USA, USA
233 Midtown Medical Center, Saskatoon, Saskatchewan, Canada, Canada
234 schema:name Charles Salt Centre, Oswestry, Shropshire, UK;, UK
235 Chesapeake Medical Research, Baltimore, Maryland, USA, USA
236 Midtown Medical Center, Saskatoon, Saskatchewan, Canada, Canada
237 rdf:type schema:Organization
238 grid-institutes:grid.239826.4 schema:alternateName Guy’s Hospital, London, UK, UK
239 schema:name Guy’s Hospital, London, UK, UK
240 rdf:type schema:Organization
241 grid-institutes:grid.254748.8 schema:alternateName Creighton University, Omaha, Nebraska, USA, USA
242 schema:name Creighton University, Omaha, Nebraska, USA, USA
243 rdf:type schema:Organization
244 grid-institutes:grid.34477.33 schema:alternateName University of Washington, Seattle, Washington, USA, USA
245 schema:name University of Washington, Seattle, Washington, USA, USA
246 rdf:type schema:Organization
247 grid-institutes:grid.412966.e schema:alternateName Limburg University Center, Diepenbeek, Belgium, and University Hospital, Maastricht, The Netherlands, The Netherlands
248 schema:name Limburg University Center, Diepenbeek, Belgium, and University Hospital, Maastricht, The Netherlands, The Netherlands
249 rdf:type schema:Organization
250 grid-institutes:grid.418758.7 schema:alternateName Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, USA, USA
251 schema:name Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, USA, USA
252 rdf:type schema:Organization
253 grid-institutes:grid.7605.4 schema:alternateName University of Turin, Turin, Italy, Italy
254 schema:name University of Turin, Turin, Italy, Italy
255 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...